Literature DB >> 6167760

Studies on the clinical significance of nonesterified and total cholesterol in urine.

D Jüngst, J Wallner, A Pickel, A Stadler, W Eiermann, F J Marx, H J Karl.   

Abstract

Gas-liquid chromatographic determinations of nonesterified and total urinary cholesterol were performed in 137 normals, 264 patients with various internal diseases without evidence of neoplasias or diseases of the kidney or urinary tract, 497 patients with malignancies and 236 patients with diseases of the kidney, urinary tract infections or prostatic adenoma with residual urine. A normal range (mean +/- 2 SD) of 0.2-2.2 mg/24 hours nonesterified cholesterol (NEC) and of 0.3-3.0 mg/24 hours total cholesterol (TC) was calculated. Values of urinary cholesterol excretion were independent of age and sex and did not correlate with cholesterol levels in plasma. Patients with various internal diseases, without evidence of neoplasias nor diseases of the kidney or obstruction of the urinary tract, showed normal urinary cholesterol excretions, as did patients with infections of the urinary tract. However, elevated urinary cholesterol was found in patients with diseases of the kidney or urinary tract obstruction (prostatic adenoma with residual urine), malignant diseases of the urogenital tract and metastasizing carcinoma of the breast. In patients with other malignant diseases urinary cholesterol was usually normal. Lesions of the urothelial cell membranes are considered to be the most likely cause of urinary cholesterol hyperexcretion. The clinical value of urinary cholesterol determinations as a possible screening test for urogenital carcinomas in unselected populations is limited by lacking specificity, expensive methodology and low prevalence of the mentioned carcinomas, although elevated urinary cholesterol excretions have been observed in early clinical stages of urogenital cancers.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6167760     DOI: 10.1007/BF01716455

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  21 in total

1.  Anisotropic lipids and urinary cholesterol excretion.

Authors:  D E COMINGS
Journal:  JAMA       Date:  1963-01-12       Impact factor: 56.272

2.  Urinary cholesterol. V. Its excretion in men with testicular and prostatic neoplasms.

Authors:  H F Acevedo; E A Campbell; E L Saier; J C Frich; L P Merkow; D W Hayeslip; S P Bartok; R C Grauer; J L Hamilton
Journal:  Cancer       Date:  1973-07       Impact factor: 6.860

3.  [Cholesterol and urinary tract diseases].

Authors:  J Frick; G Spiteller
Journal:  Z Urol Nephrol       Date:  1968-12

4.  [Nephrotic syndrome as the 1st manifestation of malignant lymphoma].

Authors:  P Kerkhoven; J Briner; A Blumberg
Journal:  Schweiz Med Wochenschr       Date:  1973-12-01

5.  Urinary cholesterol. 3. Its excretion as a protein-bound complex.

Authors:  H F Acevedo; E A Campbell
Journal:  Steroids       Date:  1970-11       Impact factor: 2.668

6.  [Urinary excretion of cholesterol in various diseases. (Especially in cancer of the urogenital system)].

Authors:  M Spiteller-Friedmann; G Spiteller; H Spiteller; J Frick
Journal:  Osterr Z Erforsch Bekampf Krebskr       Date:  1971

7.  Urinary cholesterol. VII. The significance of the excretion of nonesterified cholesterol in patients with uterine carcinomas.

Authors:  H F Acevedo; E A Campbell; J C Frich; L P Merkow; D Hayeslip; J Gilmore
Journal:  Cancer       Date:  1975-10       Impact factor: 6.860

8.  High density lipoproteinuria in nephrotic syndrome.

Authors:  S G de Mendoza; M L Kashyap; C Y Chen; R F Lutmer
Journal:  Metabolism       Date:  1976-10       Impact factor: 8.694

9.  Urinary cholesterol. VIII. Its excretion in women with ovarian neoplasms.

Authors:  H F Acevedo; E A Campbell; J C Frich; D W Hayeslip; J Gilmore
Journal:  Cancer       Date:  1976-06       Impact factor: 6.860

10.  Urinary cholesterol in cancer; urinary cholesterol excretion in cancer patients and control subjects.

Authors:  M M BURCHELL; J H O EARLE; N F MACLAGAN
Journal:  Br J Cancer       Date:  1949-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.